Clay Siegall is the CEO, president as well as the co-founder of Seattle Genetic. He is a committed man when it comes to his career thus he has become so successful. Other than his business he is also a philanthropist who highly contributes to transforming the society. Dr. Siegall graduated with a Ph.D. from George Washington University in genetics and also a B.S in Zoology from the University of Maryland. He is a successful businessman and scientist. He has a great interest in biotechnology. Siegall received an award from Maryland University in the math, natural sciences and computer of the Alumnus of 2013.
Biotechnology in simple terms is the collection of particular microorganisms so that medicine can be made by the process the microorganisms. When the manufacturing is almost done, scientists and physicians thoroughly examine these microorganisms so that they can create a good treatment for cancer. This organization is in collaboration with similar companies for the purpose of creating an excellent antibody drug conjugate (ADC). This devotion of Seattle genetic and other companies motivates the victims of cancer in a way that they will receive the best treatment more importantly good therapy. They have so far come up with Adcetric, this is their first drug and fortunately, it has reached over 60 countries.
Seattle Genetics is impressed by their achievements as a company which includes the amount they make and this indicates that their financial statement is getting higher. The organization has so far supplied more than 20 ADCs to developing clinics. Seattle Genetics has made a record of earning $330 million since it began. Moreover, their patients are well taken care of as it is required.
The next medicine that the firm has created is called SN-CD33A. Cancer type by the name acute myeloid is being treated by this drug. Luckily the medicine is progressing well in the bodies of the patients and they are doing fine. Seattle Genetics does not cease in working hard in order to create the best therapies that will treat cancer. Furthermore, the association of the firm with other organizations is also progressing well for the aim of helping so many patients worldwide.